📊 SNOA Key Takeaways
Is Sonoma Pharmaceuticals, Inc. (SNOA) a Good Investment?
Sonoma Pharmaceuticals faces critical financial distress with stagnant revenue, persistent operating losses, and unsustainable cash burn depleting its $2.6M reserve in less than one year. Despite adequate liquidity ratios and minimal debt, the deteriorating net income (-18.8% YoY) and negative returns (ROE -75.6%, ROA -19.0%) signal structural unprofitability with no visible path to operational sustainability.
Why Buy Sonoma Pharmaceuticals, Inc. Stock? SNOA Key Strengths
- Strong current ratio (2.88x) and quick ratio (2.00x) provide near-term liquidity buffer
- Low debt burden (0.00x debt/equity ratio) minimizes solvency risk from leverage
- Decent gross margin (37.5%) indicates some revenue generation capability and pricing power
SNOA Stock Risks: Sonoma Pharmaceuticals, Inc. Investment Risks
- Stagnant revenue at $14.0M with 0% YoY growth shows no business momentum or market traction
- Operating cash flow of -$3.4M against only $2.6M cash reserves creates sub-one-year solvency window
- Deteriorating profitability with net income down 18.8% YoY and negative operating margin of -15.1%
- Return metrics deeply negative (ROE -75.6%, ROA -19.0%) indicating value destruction
- Zero insider Form 4 filings in 90 days suggests lack of management confidence in recovery
Key Metrics to Watch
- Operating cash flow trajectory - current -$3.4M burn rate determines survival timeline
- Revenue growth rate - company requires immediate top-line acceleration to achieve profitability
- Cash position depletion - critical threshold approaching with <$2.6M reserves and continuing losses
Sonoma Pharmaceuticals, Inc. (SNOA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.88x current ratio provides a solid financial cushion.
SNOA Profit Margin, ROE & Profitability Analysis
SNOA vs Healthcare Sector: How Sonoma Pharmaceuticals, Inc. Compares
How Sonoma Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Sonoma Pharmaceuticals, Inc. Stock Overvalued? SNOA Valuation Analysis 2026
Based on fundamental analysis, Sonoma Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Sonoma Pharmaceuticals, Inc. Balance Sheet: SNOA Debt, Cash & Liquidity
SNOA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Sonoma Pharmaceuticals, Inc.'s revenue has declined by 23% over the 5-year period, indicating business contraction. The most recent EPS of $-10.63 indicates the company is currently unprofitable.
SNOA Revenue Growth, EPS Growth & YoY Performance
SNOA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $3.6M | -$534.0K | $-0.48 |
| Q2 2026 | $3.6M | -$534.0K | $-0.32 |
| Q1 2026 | $3.4M | -$1.1M | $-0.76 |
| Q3 2025 | $3.1M | -$610.0K | $-0.63 |
| Q2 2025 | $2.7M | -$610.0K | $-0.59 |
| Q1 2025 | $3.4M | -$1.1M | $-0.07 |
| Q3 2024 | $2.9M | -$866.0K | $-0.08 |
| Q2 2024 | $2.7M | -$887.0K | $-0.29 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Sonoma Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
SNOA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Sonoma Pharmaceuticals, Inc. (CIK: 0001367083)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SNOA
What is the AI rating for SNOA?
Sonoma Pharmaceuticals, Inc. (SNOA) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SNOA's key strengths?
Claude: Strong current ratio (2.88x) and quick ratio (2.00x) provide near-term liquidity buffer. Low debt burden (0.00x debt/equity ratio) minimizes solvency risk from leverage.
What are the risks of investing in SNOA?
Claude: Stagnant revenue at $14.0M with 0% YoY growth shows no business momentum or market traction. Operating cash flow of -$3.4M against only $2.6M cash reserves creates sub-one-year solvency window.
What is SNOA's revenue and growth?
Sonoma Pharmaceuticals, Inc. reported revenue of $14.0M.
Does SNOA pay dividends?
Sonoma Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find SNOA SEC filings?
Official SEC filings for Sonoma Pharmaceuticals, Inc. (CIK: 0001367083) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SNOA's EPS?
Sonoma Pharmaceuticals, Inc. has a diluted EPS of $-1.56.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SNOA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Sonoma Pharmaceuticals, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SNOA stock overvalued or undervalued?
Valuation metrics for SNOA: ROE of -75.6% (sector avg: 15%), net margin of -18.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SNOA stock in 2026?
Our dual AI analysis gives Sonoma Pharmaceuticals, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SNOA's free cash flow?
Sonoma Pharmaceuticals, Inc.'s operating cash flow is $-3.4M, with capital expenditures of $163.0K. FCF margin is -25.6%.
How does SNOA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -18.6% (avg: 12%), ROE -75.6% (avg: 15%), current ratio 2.88 (avg: 2).